BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37051743)

  • 1. Characterization of a novel
    Van Outersterp I; Hormann FM; Hoogkamer AQ; Boeree A; Van den Broek SA; Den Boer ML; Boer JM
    Haematologica; 2023 Oct; 108(10):2859-2864. PubMed ID: 37051743
    [No Abstract]   [Full Text] [Related]  

  • 2. MEF2D-BCL9 B-Lymphoblastic Leukemia Blast Morphology Does Not Always Mimic Mature B-Cell Leukemia.
    Baek HJ; Choi YJ; Kim BR; Lee JH; Shin MG; Kook H
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):112-113. PubMed ID: 33235148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and molecular characteristics of
    Ohki K; Kiyokawa N; Saito Y; Hirabayashi S; Nakabayashi K; Ichikawa H; Momozawa Y; Okamura K; Yoshimi A; Ogata-Kawata H; Sakamoto H; Kato M; Fukushima K; Hasegawa D; Fukushima H; Imai M; Kajiwara R; Koike T; Komori I; Matsui A; Mori M; Moriwaki K; Noguchi Y; Park MJ; Ueda T; Yamamoto S; Matsuda K; Yoshida T; Matsumoto K; Hata K; Kubo M; Matsubara Y; Takahashi H; Fukushima T; Hayashi Y; Koh K; Manabe A; Ohara A;
    Haematologica; 2019 Jan; 104(1):128-137. PubMed ID: 30171027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of MEF2D fusion in human B-cell precursor acute lymphoblastic leukemia cell lines.
    Akahane K; Yasuda T; Tsuzuki S; Hayakawa F; Kiyokawa N; Somazu S; Watanabe A; Kagami K; Abe M; Harama D; Goi K; Kawazu M; Kojima S; Imamura T; Goto H; Iwamoto S; Minegishi M; Abe M; Hojo H; Inaba T; Mano H; Sugita K; Inukai T
    Hematol Oncol; 2020 Oct; 38(4):614-617. PubMed ID: 32515032
    [No Abstract]   [Full Text] [Related]  

  • 5. MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents.
    Suzuki K; Okuno Y; Kawashima N; Muramatsu H; Okuno T; Wang X; Kataoka S; Sekiya Y; Hamada M; Murakami N; Kojima D; Narita K; Narita A; Sakaguchi H; Sakaguchi K; Yoshida N; Nishio N; Hama A; Takahashi Y; Kudo K; Kato K; Kojima S
    J Clin Oncol; 2016 Oct; 34(28):3451-9. PubMed ID: 27507882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical characteristics and outcomes of childhood B-ALL with ZNF384 and MEF2D rearrangements].
    Hirabayashi S; Manabe A; Ohki K; Kiyokawa N
    Rinsho Ketsueki; 2023; 64(7):633-638. PubMed ID: 37544723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.
    Gu Z; Churchman M; Roberts K; Li Y; Liu Y; Harvey RC; McCastlain K; Reshmi SC; Payne-Turner D; Iacobucci I; Shao Y; Chen IM; Valentine M; Pei D; Mungall KL; Mungall AJ; Ma Y; Moore R; Marra M; Stonerock E; Gastier-Foster JM; Devidas M; Dai Y; Wood B; Borowitz M; Larsen EE; Maloney K; Mattano LA; Angiolillo A; Salzer WL; Burke MJ; Gianni F; Spinelli O; Radich JP; Minden MD; Moorman AV; Patel B; Fielding AK; Rowe JM; Luger SM; Bhatia R; Aldoss I; Forman SJ; Kohlschmidt J; Mrózek K; Marcucci G; Bloomfield CD; Stock W; Kornblau S; Kantarjian HM; Konopleva M; Paietta E; Willman CL; Loh ML; Hunger SP; Mullighan CG
    Nat Commun; 2016 Nov; 7():13331. PubMed ID: 27824051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEF2D-rearranged acute lymphoblastic leukemia resembles Burkitt lymphoma/leukemia.
    Sun J; Yu W; Zhang X
    Ann Hematol; 2020 Jan; 99(1):185-188. PubMed ID: 31781846
    [No Abstract]   [Full Text] [Related]  

  • 9. Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity.
    Hirano D; Hayakawa F; Yasuda T; Tange N; Yamamoto H; Kojima Y; Morishita T; Imoto N; Tsuzuki S; Mano H; Naoe T; Kiyoi H
    Oncogene; 2019 Mar; 38(13):2263-2274. PubMed ID: 30478446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion.
    Zhang M; Zhang H; Li Z; Bai L; Wang Q; Li J; Jiang M; Xue Q; Cheng N; Zhang W; Mao D; Chen Z; Huang J; Meng G; Chen Z; Chen SJ
    Blood; 2022 Sep; 140(12):1390-1407. PubMed ID: 35544603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia.
    Prima V; Gore L; Caires A; Boomer T; Yoshinari M; Imaizumi M; Varella-Garcia M; Hunger SP
    Leukemia; 2005 May; 19(5):806-13. PubMed ID: 15744350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of immunophenotypic characteristics on genetic subgrouping in childhood acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group (TCCSG) study L04-16.
    Ohki K; Takahashi H; Fukushima T; Nanmoku T; Kusano S; Mori M; Nakazawa Y; Yuza Y; Migita M; Okuno H; Morimoto A; Yoshino H; Kato M; Hayashi Y; Manabe A; Ohara A; Hasegawa D; Inukai T; Tomizawa D; Koh K; Kiyokawa N;
    Genes Chromosomes Cancer; 2020 Oct; 59(10):551-561. PubMed ID: 32368831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia.
    Tsuzuki S; Yasuda T; Kojima S; Kawazu M; Akahane K; Inukai T; Imaizumi M; Morishita T; Miyamura K; Ueno T; Karnan S; Ota A; Hyodo T; Konishi H; Sanada M; Nagai H; Horibe K; Tomita A; Suzuki K; Muramatsu H; Takahashi Y; Miyazaki Y; Matsumura I; Kiyoi H; Hosokawa Y; Mano H; Hayakawa F
    Blood Cancer Discov; 2020 Jul; 1(1):82-95. PubMed ID: 34661142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staurosporine and venetoclax induce the caspase-dependent proteolysis of MEF2D-fusion proteins and apoptosis in MEF2D-fusion (+) ALL cells.
    Tange N; Hayakawa F; Yasuda T; Odaira K; Yamamoto H; Hirano D; Sakai T; Terakura S; Tsuzuki S; Kiyoi H
    Biomed Pharmacother; 2020 Aug; 128():110330. PubMed ID: 32504922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pathogenic role of MEF2D-SS18 fusion gene in B-cell acute lymphoblastic leukemia.
    Zhang M; Mao D; Zhang W
    Biochem Biophys Res Commun; 2018 Feb; 496(4):1331-1336. PubMed ID: 29408457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome and molecular measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia patients with MEF2D fusions.
    Sun K; Chen WM; Wang X; Zhao XS; Li LD; Hao Y; Wang J; Xu N; Jiang Q; Jiang H; Xu LP; Wang Y; Zhang XH; Huang XJ; Qin YZ
    Hematol Oncol; 2023 Aug; 41(3):594-597. PubMed ID: 36516881
    [No Abstract]   [Full Text] [Related]  

  • 17.
    Sadras T; Müschen M
    Blood Cancer Discov; 2020 Jul; 1(1):18-20. PubMed ID: 34661138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mature B-cell acute lymphoblastic leukaemia associated with a rare MLL-FOXO4 fusion gene.
    Lim L; Chen KS; Krishnan S; Gole L; Ariffin H
    Br J Haematol; 2012 Jun; 157(6):651. PubMed ID: 22429121
    [No Abstract]   [Full Text] [Related]  

  • 19. Concurrent novel RGS17::BCL9 fusion and basophilia in T/B mixed phenotype acute lymphoblastic leukemia/lymphoma.
    Huang X; Jiang L; Li T; Yang M
    Int J Lab Hematol; 2024 Jun; 46(3):561-563. PubMed ID: 38253341
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging molecular subtypes and therapies in acute lymphoblastic leukemia.
    Davis K; Sheikh T; Aggarwal N
    Semin Diagn Pathol; 2023 May; 40(3):202-215. PubMed ID: 37120350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.